# Peter Attia's ApoB & Lipid Risk Reduction Protocol - Clinical Longevity Review & Consensus Audit

> **Consensus Verdict**: Apolipoprotein B vs LDL cholesterol in cardiovascular risk prediction (Sniderman AD, et al., JAMA Cardiol 2019; Ference BA, et al., JACC 2019).

## 1. Executive Summary & Scores
- **Longevity Evidence Score**: **83/100**
- **Evidence Quality Tier**: **bronze**
- **Human Clinical Evidence Strength**: 72/100
- **Primary Longevity Classification**: other
- **Safety Margin Score**: 84/100 (Higher is safer)
- **Time Burden**: ~15 minutes/day
- **Estimated Monthly Cost**: inexpensive
- **Adherence Friction**: 3/10 (Lower is easier to sustain)

---

## 2. Biological Mechanisms of Action
ApoB is the single protein surface marker present on all atherogenic lipoproteins (LDL, VLDL, IDL, Lp(a)). Lowering ApoB particle concentration prevents endothelial entrapment, subendothelial oxidation, and macrophage foam cell formation.

---

## 3. Canonical Longevity Vector Impacts (The 8 Longevity Pillars)

---

## 4. Practical Protocol & Administration Guidelines
- **Standard Clinical Dosage**: Target ApoB <60 mg/dL (Quarterly Lab Tracking)
- **Recommended Timing**: Quarterly Diagnostics & Lifestyle Adjustment
- **Administration Type**: behavioral
- **Recommended Biomarkers to Monitor**: energy

---

## 5. Safety, Contraindications & Drug Interactions
- **Contraindications**: None reported in standard human trials with recommended doses.
- **Safety Profile**: safe - Regular liver panel monitoring if using lipid-lowering pharmacotherapy under physician supervision.

---

## 6. Peer-Reviewed Human Clinical Trials & Key PMIDs
1. **Clinical utility of apolipoprotein B in routine cardiovascular risk management** [PMID: 29874534]
   - Link: https://pubmed.ncbi.nlm.nih.gov/29874534/
2. **Low-density lipoproteins cause atherosclerotic cardiovascular disease** [PMID: 28444290]
   - Link: https://pubmed.ncbi.nlm.nih.gov/28444290/
3. **Apolipoprotein B Particles, Not Cholesterol, Determine the Risk of Myocardial Infarction** [PMID: 31215987]
   - Link: https://pubmed.ncbi.nlm.nih.gov/31215987/
4. **Apolipoprotein B, LDL-C, and Triglycerides as Predictors of Myocardial Infarction: The Copenhagen General Population Study** [PMID: 32912443]
   - Link: https://pubmed.ncbi.nlm.nih.gov/32912443/

---

## 7. Canonical Citation & Web Verification
- **Official Web Review**: [Peter Attia's ApoB & Lipid Risk Reduction Protocol on LongevityReviews](https://longevityreviews.org/modalities/attia_apob_lipid_management)
- **Last Evidence Calibration**: 2026-08-08
- **Review Policy**: 0% sponsored placements, independent peer-reviewed consensus.